
-
Lyell Immunopharma NasdaqGS:LYEL Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Location: 201 Haskins Way, South San Francisco, CA, 94080, United States | Website: https://www.lyell.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-121.5M
Cash
301.2M
Avg Qtr Burn
-43.78M
Short % of Float
2.91%
Insider Ownership
13.73%
Institutional Own.
66.41%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYL314 Details Cancer, Blood cancer, B-cell lymphoma | Phase 1/2 Data readout | |
LYL119 Details Solid tumor/s, Cancer | Failed Discontinued | |
LYL797 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer | Failed Discontinued | |
LYL845 Details Solid tumor/s, Cancer, Colorectal cancer , Non-small cell lung carcinoma, Melanoma | Failed Discontinued |